We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Boehringer’s Pradaxa Gains Additional European Indication

Boehringer’s Pradaxa Gains Additional European Indication

June 6, 2014

Boehringer Ingelheim announced Friday that the European Commission had approved Pradaxa (dabigatran etexilate) to treat and prevent the recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).

The FDA approved Pradaxa for the treatment of DVT and PE patients earlier this year.
The approval by the EC comes on the heels of a positive opinion issued by the Committee for Medicinal Products for Human Use of the European Medicines Agency, and is based on results from three phase III clinical trials that established the efficacy of Pradaxa, the German drugmaker said.

Additionally, results from a fourth study demonstrated a reduction of 92 percent in the risk of recurrent blood clots in patients who received Pradaxa compared to placebo. Safety data demonstrated that DVT or PE patients receiving Pradaxa had noticeably lower rates of bleeding compared with those on warfarin, leading to a good overall safety profile, the company said.

Pradaxa has the more clinical trial experience in DVT and PE patients than any other novel oral anticoagulant, BI noted.

DVT and PE can be very dangerous — nearly one in three PE patients dies within three months and 40 percent of patients suffer a repeat blood clot within 10 years of the first one.

The drug also has EU licensure for the primary prevention of venous thromboembolism, a collective term for DVT and PE, in patients who have undergone total knee or hip replacement surgery, BI said. — Kellen Owings

Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.

Pharmaceuticals Submissions and Approvals

Upcoming Events

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Purple_Approved_Stamp.gif

    Seno Medical Gets Premarket Approval for Breast Cancer Diagnostic

  • Triple Vaccine, needles

    Moderna to Start New Trial Adding Third Shot of COVID-19 Vaccine

  • Supreme Court Rejects Merck’s Appeal for $2.5 Billion Patent Verdict Reinstatement

  • FDA clears text

    FDA Clears SCC’s Transfusion-Management Software

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing